Relmada acquires neurosteroid from Asarina

Relmada acquires Tourette’s therapy rights from Asarina
Relmada has acquired complete ownership rights to Sepranolone, developed for Tourette syndrome (TS) from Asarina Pharma.
Relmada in-licenses Tourette syndrome drug from Asarina
US CNS specialist Relmada Therapeutics has announced the acquisition of sepranolone, a Phase IIb ready neurosteroid, from Sweden’s Asarina Pharma, being developed for the potential treatment of Tourette syndrome (TS) and other compulsive disorders.
Relmada Therapeutics acquires Sepranolone from Asarina Pharma
Relmada Therapeutics (RLMD) announced the acquisition of Sepranolone, a Phase 2b ready neurosteroid, from Asarina Pharma AB, being developed
Relmada acquires new Tourette syndrome treatment asset
CORAL GABLES, Fla. - Relmada Therapeutics , Inc. (NASDAQ:RLMD), a clinical-stage biotechnology firm with a market capitalization of $11.5 million, has announced the acquisition of Sepranolone, a Phase 2b ready neurosteroid,
Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB
Relmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related conditions from Asarina Pharma AB. Phase 2a results
Psychedelic: Relmada acquires neurosteroid from Asarina
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on an acquisition, study results
FierceBiotech3d
After phase 3 miss, Relmada picks up midstage Tourette's asset from Swedish biotech
Relmada, which has turned to strategic options after scrapping two phase 3 trials in major depressive disorder (MDD), is ...
Mizuho maintains Neutral on Relmada stock, sees deal potential
Mizuho (NYSE:MFG) analysts maintained their Neutral rating on Relmada Therapeutics Inc (NASDAQ:RLMD), with a steady price target of $1.00, following the announcement of a new acquisition. The stock, ...
Nasdaq4d
Relmada Therapeutics Acquires Sepranolone from Asarina Pharma for Tourette Syndrome Treatment Development
Relmada Therapeutics has announced the acquisition of Sepranolone, a Phase 2b ready neurosteroid developed for treating Tourette syndrome (TS) and related compulsive disorders, from Asarina Pharma ...